Last Updated on January 5, 2024 by The Health Master
Pharma MSMEs
The Gujarat Food and Drug Control Administration (FDCA) has issued show cause notices to three pharma MSMEs in Ahmedabad and Baroda for gross violations of good manufacturing practices (GMP) norms.
The companies have been asked to stop production immediately and furnish reports on quality control and GMP compliance.
The FDCA’s crackdown is part of a series of risk-based inspections being carried out all over India as a result of reports that Indian pharmaceutical companies were exporting contaminated medications.
Round of inspections: Pharma MSMEs
In the latest round of inspections, the FDCA has also canceled the license of one section of a company that produced unstable products with multiple quality failures.
The risk-based inspections are based on current good manufacturing practices (cGMP) and good laboratory practices (GLP) under the Drugs and Cosmetics (D&C) Rules, 1945.
The inspections cover a wide range of areas, including sanitation, hygiene, self-inspection, quality audits, prevention of cross-contamination, and bacterial contamination during production.
The FDCA’s actions are a clear signal that the government is taking the issue of pharmaceutical quality very seriously.
The inspections are also a reminder to pharma companies that they must comply with GMP norms in order to protect public health.
Observations
Risk-based inspections:
The FDCA is conducting risk-based inspections of pharma companies to audit their compliance with GMP norms. These inspections are based on the company’s size, location, history of compliance, and the type of products they manufacture.
GMP violations:
The FDCA has found a number of GMP violations at the three pharma MSMEs in Ahmedabad and Baroda.
These violations include:
- Poor sanitation and hygiene practices
- Inadequate quality control measures
- Lack of proper documentation
- Failure to prevent cross-contamination
- Bacterial contamination of products
Show cause notices:
The FDCA has issued show cause notices to the three pharma MSMEs. The companies have been asked to explain why their licenses should not be cancelled.
Possible penalties:
If the companies are found guilty of violating GMP norms, their licenses could be canceled. They could also be fined or imprisoned.
Impact on patients:
The GMP violations at these pharma MSMEs could have a serious impact on patients. Medicines that are not manufactured in accordance with GMP norms may not be safe or effective.
Must read: Understanding GMP, cGMP, and WHO-GMP
Major Key Points:
- The Gujarat FDCA has issued show cause notices to three pharma MSMEs in Ahmedabad and Baroda for gross violations of GMP norms.
- The companies have been asked to stop production immediately and furnish reports on quality control and GMP compliance.
- The FDCA’s crackdown is part of a series of risk-based inspections being carried out all over India as a result of reports that Indian pharmaceutical companies were exporting contaminated medications.
- In the latest round of inspections, the FDCA has also canceled the license of one section of a company that produced unstable products with multiple quality failures.
- The risk-based inspections are based on current good manufacturing practices (cGMP) and good laboratory practices (GLP) under the Drugs and Cosmetics (D&C) Rules, 1945.
- The inspections cover a wide range of areas, including sanitation, hygiene, self-inspection, quality audits, prevention of cross-contamination, and bacterial contamination during production.
- The FDCA’s actions are a clear signal that the government is taking the issue of pharmaceutical quality very seriously.
- The inspections are also a reminder to pharma companies that they must comply with GMP norms in order to protect public health.
Conclusion:
The Gujarat FDCA’s crackdown on pharma MSMEs for GMP violations is a welcome move. It is important to ensure that medicines are manufactured in a safe and hygienic manner.
The FDCA’s actions should send a strong message to pharma companies that they will be held accountable for violating GMP norms.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Dissolution test: Importance in Pharma Industry
NSQ Drug: Route cause analysis and CAPA
Types of inspections done by USFDA: Read in detail
USFDA issues Form 483 to Pharma Companies: Let’s know all about it
Licensing procedure for manufacturing of Drugs
Procedure to obtain License to Manufacture drugs for testing and analysis purposes
Latest Notifications regarding Pharmaceuticals
Latest Notifications: D&C Act 1940
Latest Notifications: D&C Rules 1945
Latest Notifications: Banned Drugs
Latest Notifications: NDPS Act
Pharma Industry Gears Up for Revised Schedule M: Gujarat
Drug recall: Glenmark recalls this High BP drug due to quality reasons
Trademark Protection of medicine branding upheld by Delhi High Court
Revolutionary Device: New Technology for Diabetes Detection and Management
USFDA issues Form 483 with 2 observations to Gland Pharma: Hyderabad
Regulation of E-Pharmacies: Stakeholder meeting with DCGI
NABL certification for Laboratories: Let’s understand
Huge quantities of drugs seized from Nigerian: UP
Drug alert: 51 out of 1306 samples declared as NSQ in July 2023
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
